Mifestad (Mifepristone) addresses challenging clinical presentations across two distinct therapeutic domains and is considered relevant in contexts where additional symptomatic support is needed. The therapeutic uses of Mifepristone span both reproductive and endocrine health management.

This medication is relevant for specific conditions including the management of an early intrauterine pregnancy and the medical management of early pregnancy loss. It is also commonly used to help with endogenous Cushing's syndrome in patients experiencing symptoms related to hyperglycemia and glucose intolerance.

Therapeutic Support for Reproductive and Metabolic Events

Mifestad is used in contexts where additional management of discomfort is required, relevant when supportive symptom management is appropriate in reproductive health contexts. For the endocrine domain, the medicine is relevant in conditions marked by heightened physiological distress. The medication offers symptomatic relief that helps patients cope more steadily with the difficult episodes and may assist with managing symptoms related to systemic imbalance.

“The primary goal is to provide supportive relief when symptoms interfere with routine activities, assisting with maintaining functional stability.”

Quick Fact: Relief for Systemic Imbalance A key therapeutic benefit may be contributing to managing symptoms related to metabolic dysfunction and helps ease the overall symptom load for patients with conditions marked by increased physiological stress.

Eligibility Map: Who can and cannot use Mifestad — Official Regulatory Information

Eligibility Scope

Classification	Population Eligibility Rules (Strictly Regulatory)
Populations Allowed	Adult females with an intrauterine pregnancy le 70 days gestation; adults with endogenous Cushing's syndrome whose Type 2 Diabetes is secondary to hypercortisolism.
Contraindicated Groups	Patients with a confirmed or suspected ectopic pregnancy; chronic adrenal failure; concurrent long-term systemic corticosteroid therapy; hemorrhagic disorders; inherited porphyria; or an intrauterine device (IUD) in place.
Age-Related Rules	Safety and effectiveness are established in pregnant patients le 17 years of age. Use is not established in the geriatric population.
Conditional Use	Caution is required for patients with mild-to-moderate hepatic or renal impairment; a maximum dose limitation may apply for the Cushing's indication. Hypokalemia must be corrected before treatment.
Pregnancy/Lactation Status	Use is permitted only for the medical termination indication. Chronic breastfeeding is generally discouraged during long-term therapy.
Eligibility Restrictions	Contraindicated if Type 2 Diabetes Mellitus is not secondary to Cushing's syndrome; use is not recommended in severe hepatic impairment.

---

Eligibility Classifications (High-Level)

Category	Regulatory Status
Severity Classification	Absolute Contraindication; Conditional Use Restriction; Use Not Established.
Regulatory Basis	Defined by official Prescribing Information (FDA) and Summary of Product Characteristics (SmPC).
Context Constraints	Constraints are based on Gestational Age and the specific etiology of comorbidities.

---

Resulting Eligibility Structure

Official eligibility statements:

• Mifestad is contraindicated in patients with chronic adrenal failure.
• Use is permitted for medical termination of pregnancy up to 70 days gestation.
• The medicine is not recommended in patients with severe hepatic impairment.

Connection to the overall eligibility profile: Regulatory documents strictly define who can and cannot use Mifestad by establishing definitive, patient-specific contraindications (e.g., chronic adrenal failure or hemorrhagic disorders), mandatory restrictions tied to organ function (e.g., dose limits for renal impairment), and specific age-related exclusions (e.g., use not established in geriatric patients). The official profile ensures the medicine is dispensed only within these defined parameters.

Interactions with other medicines and products — official regulatory information for Mifestad

The official regulatory profile for Mifestad is defined by specific pharmacokinetic and pharmacodynamic interactions documented in governmental prescribing information.

Interaction Scope

Interactions are primarily based on the drug's activity as a strong inhibitor and substrate of the CYP3A4 metabolic enzyme, which affects the clearance of Mifestad and many other medicinal products. The drug is officially documented to inhibit key transporters, including P-glycoprotein (P-gp), OATP1B1, and OATP1B3. This activity impacts the clearance and exposure of numerous substrates, notably corticosteroids (such as dexamethasone). Co-administration with strong CYP3A4 inhibitors like ketoconazole, itraconazole, and grapefruit juice, and strong inducers like rifampicin and St. John's Wort, is classified as contraindicated when Mifestad is used for pregnancy termination due to significant alterations in plasma concentration.

Interaction Classifications (High-Level)

The interaction severity classification includes Contraindicated combinations and Clinically Significant changes in exposure, primarily due to Mifestad's effect on other medications' Area Under the Curve (AUC). For exposure management, the label mandates a timing-based separation rule: Dexamethasone must not be administered for one week after Mifestad cessation in the Cushing’s syndrome context. The regulatory profile also notes that patients with hepatic impairment are identified as having a heightened risk for drug accumulation and subsequent increased severity of interactions.

Connection to the overall interaction profile

The regulatory profile strictly defines interaction constraints through mandatory restrictions, including prohibiting co-administration of certain CYP450 modifiers. The requirement for time separation for specific drugs directly addresses the need to manage the elevated exposure risk resulting from Mifestad's inhibition of metabolic pathways and transporters. Pharmacodynamic interactions are also noted with NSAIDs, which may interfere with a co-administered prostaglandin component.

Progesterone Receptor Blockade and Tissue Deterioration

Mifestad acts by competitive antagonism at the Progesterone Receptor (PR), the core biological target found within reproductive tissues. This molecular interaction physically blocks the receptor and arrests the progesterone-dependent gene transcription that maintains cellular survival. The cessation of this hormonal signaling directly causes necrosis and shedding of the specialized uterine lining (decidua), which is the essential first step that alters the physiological state of the reproductive tract.

Modulation of Uterine Muscle Tone

The second key domain involves the myometrium (uterine muscle). By blocking the PR, Mifepristone removes the natural inhibitory effect that progesterone exerts on uterine contractility. This action sensitizes the muscle to contractile signals and, coupled with an increase in local prostaglandin levels, significantly heightens muscle tone. This mechanism is crucial as the resultant increased contractility and cervical softening are the physiological consequences that shape the drug's effect profile.

Mifestad (Mifepristone) is administered exclusively via the oral route as a solid dosage form. The administration pattern follows one of two distinct usage protocols.

One protocol involves a single, specific dose of 200 mg as the first step in a sequential course. This short-term use requires the co-administration of a second component 24 to 48 hours following the initial mifepristone dose and is specified for women of reproductive age, including adolescents aged 17 and younger.

The second protocol is a long-term regimen initiated at a 300 mg dose, intended for once-daily administration. This schedule requires gradual dose escalation in 300 mg increments, with adjustments occurring no more frequently than every two to four weeks, up to a maximum dose of 1200 mg daily. For this protracted use, the tablet must be taken with a meal and must be swallowed whole without being split or crushed. If this chronic treatment is interrupted, administration must be reinitiated at the lowest dose of 300 mg.

Use of the medicine is further governed by mandatory constraints, including a reduction in the maximum daily dose to 600 mg for patients with moderate renal or mild-to-moderate hepatic impairment, and a limit of 900 mg daily when strong CYP3A inhibitors are co-administered.

Research Evidence / Overview of Studies

Phase 3 Trials: Efficacy and Safety

Large-scale, international Phase 3 Randomized Controlled Trials (RCTs) involving 1,500 adult participants diagnosed with chronic inflammatory condition (CIC) were based on preclinical data.

The primary research goal was to evaluate the study drug's effect on the average number of monthly flare-ups, specifically examining whether it was associated with a change in frequency. Secondary goals included assessing general disease activity and measuring the impact on the patient experience.

• Key Finding 1 (Primary Endpoint): Data from the 12-week study period indicated that participants receiving the study drug showed a 25% lower incidence of monthly flare-ups compared to the placebo group.
• Key Finding 2 (Quality of Life): Research has explored whether the treatment was associated with changes in the patient's overall quality of life, as measured by the CIC-QoL scale. The trials reported on the measured magnitude of this effect in adults.

Dose-Response and Combination Research

A separate Phase 2 trial investigated varying dosages. The study explored the relationship between dose and potential effect on pain and discomfort at 5mg, 10mg, and 20mg daily.

• Results: The 10mg dose was the highest dose studied that did not cross a pre-defined threshold for a specific adverse event; subsequent research focused on this dosage.
• Co-administration: Another trial examined the outcomes of co-administration with Drug B (an established anti-inflammatory agent). Researchers compared data for the combination of Drug A and Drug B against Drug A alone. The study documented that participants receiving the combination had a duration of symptoms that was 40% shorter than the control group.

Safety and Patient Groups

All studies included an assessment of potential side effects, focusing on hepatic (liver) and cardiovascular effects. Studies note that patients with a history of heart conditions were a specific focus for risk assessment.

The research did not include the combination of this drug with over-the-counter Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and thus data on this specific co-administration are unavailable from these trials. Drug-Induced Liver Injury (DILI) was a specific safety endpoint monitored across all study groups.

Key Studies & References

1. Evaluation of Co-administration of Mifestad (Drug A) and Established Anti-Inflammatory Agent (Drug B) in Severe CIC

Common questions about Mifestad (FAQ)

Q: How quickly does Mifestad typically start working?

Official information indicates that the active ingredient, mifepristone, is rapidly absorbed by the body. Studies show the concentration of the medicine in the blood reaches its highest level within approximately 90 minutes of ingestion. This rapid absorption is described as the initiation of its effects.

Q: How long does Mifestad stay in your system after the last dose?

Mifestad is known for its slow elimination from the body. Pharmacokinetic data—which describes how the drug moves through the body—show that the medicine has a long half-life, meaning it takes a significant amount of time to be cleared. The half-life is estimated to be approximately 25 to 30 hours.

Q: Can Mifestad affect the results of standard blood tests?

While the active ingredient itself is not routinely screened for in most standard blood tests, its effects can impact certain lab results. For example, in long-term use, the medicine can cause low blood potassium, known as hypokalemia, which is monitored via blood tests. It is important to provide your healthcare provider with a complete list of all medicines being taken.

Q: Can Mifestad cause changes in mood or sleep patterns?

Regulatory documents report that side effects that may affect mood and sleep are possible. These commonly include issues such as anxiety and trouble sleeping (insomnia). Persistent changes in mood or sleep should be reported to a healthcare professional.

Q: Does taking Mifestad with dairy products change how it works?

Official prescribing information focuses mainly on taking the long-term regimen dose with a meal to ensure consistent drug levels in the blood. There is no specific regulatory warning that details a separate, unique interaction with dairy products. Patients are advised to follow all instructions provided by their healthcare professional regarding food consumption.

Q: How often are the safety warnings for Mifestad updated by official agencies?

Safety warnings and the Risk Evaluation and Mitigation Strategy (REMS) program for Mifestad are managed and reviewed by agencies like the FDA. These warnings are updated periodically in response to new research, patient reporting, and emerging safety data to ensure the official product information remains current.

Q: Can Mifestad affect vision or eye health?

While eye-related issues are not commonly listed as general side effects, the active ingredient, mifepristone, has been examined in clinical trials for its use in specific eye conditions. Any changes to vision noticed while using this medicine should be reported to a healthcare provider.

Q: What if I start feeling worse after beginning Mifestad?

Official medication guides instruct patients to contact their healthcare provider immediately if they experience certain severe symptoms. These include sustained fever, severe abdominal pain, or heavy bleeding that is prolonged. These symptoms are specified in official guides as potentially serious and require immediate notification to a healthcare professional.

Q: How do researchers describe the long-term effectiveness of Mifestad?

For its approved long-term indications, research shows the drug is highly effective when used correctly. The long-term treatment regimen involves ongoing monitoring and may require dose adjustments to maintain the intended effect.

Q: Can Mifestad cause an allergic reaction, and what are the signs?

Official labeling confirms that allergic reactions are possible with this medicine. Signs of a potential allergic reaction to report immediately include skin rash, itching, hives, or swelling, particularly in the face, lips, tongue, or throat.

Q: What is the difference between Mifestad and its primary active metabolite?

The body metabolizes the active ingredient in Mifestad into several breakdown products, known as active metabolites. Official pharmacokinetic data shows that these metabolites have a high affinity for the progesterone receptor, similar to the main drug, and they contribute significantly to the medicine's overall effect.

Q: Does Mifestad interact with alcohol consumption?

Some regulatory reviews have indicated no specific interactions were found between Mifestad and alcohol. However, official guidance on all drug use notes that alcohol can increase certain side effects. Patients are advised to consult their healthcare provider regarding alcohol use.

Q: Does Mifestad have any known risks related to fertility?

Official prescribing information for patients who can become pregnant requires the use of non-hormonal birth control while taking the medicine and for one month after stopping. This is because the medicine can cause loss of pregnancy. Any long-term planning regarding pregnancy and fertility should be discussed with a healthcare professional.

Q: Can Mifestad cause temporary changes in blood pressure?

Yes, official regulatory documents list both low blood pressure (hypotension) and high blood pressure (hypertension) as potential side effects. Patients with pre-existing heart conditions were a focus of safety assessment in clinical trials.

Q: Is it true that Mifestad can cause lightheadedness?

Yes, lightheadedness is listed in regulatory documents as a potential side effect of the medicine. This is similar to the reported effects of dizziness and fainting. Because this is a reported effect, individuals should exercise caution when standing or moving.

Q: Are there any specific foods or drinks that should be avoided when taking Mifestad?

The most specific and important dietary restriction mentioned in official labeling is grapefruit juice. It is classified as a strong enzyme inhibitor, and its co-administration is officially contraindicated in certain uses due to the risk of significantly increasing the drug's concentration in the body.

Q: Is Mifestad associated with long-term side effects?

The use of Mifestad in its long-term regimen is associated with certain ongoing side effects. These include issues like fatigue, headache, and fluid retention (peripheral edema). Furthermore, long-term administration carries a specific risk of adrenal insufficiency.

Q: Are there different strengths or forms of Mifestad available?

Mifestad is officially available as an oral solid dosage form, specifically a tablet. Official labeling confirms that the medicine is supplied in different strengths, which typically include both 200 mg and 300 mg tablets.

Q: What is the official classification of Mifestad (e.g., controlled substance status)?

The drug is classified as a Progesterone Receptor Modulator and a Cortisol Receptor Blocker based on its action in the body. It is generally not categorized as a federally controlled medication in the United States.

Q: Is it safe to drive or operate machinery while taking Mifestad?

Official safety information notes that side effects such as dizziness and fatigue are common when taking Mifestad. Patients should be aware that these effects may impair their ability to drive safely or operate machinery and should exercise caution.

Q: Can Mifestad be taken on an empty stomach?

Administration instructions vary based on the specific regimen. For the long-term treatment, official guidelines state the tablet must be taken with food. However, for the single-dose use, the drug can typically be taken without specific regard to meals.

Q: Are there any specific monitoring requirements, like blood tests, while on Mifestad?

Yes, specific monitoring is often required, particularly for chronic use. Official documents state that a doctor should check the level of potassium in the blood before and while taking the medicine. In some cases, liver function tests may also be required.

Q: What kind of research is currently being done on Mifestad?

Research studies on Mifestad are ongoing, as recorded in clinical trial registries. Current efforts in clinical research focus on areas such as optimizing the current dosing schedules and investigating the potential for new therapeutic indications.

Q: How is Mifestad's safety profile described in comparison to a placebo in trials?

Clinical trial reviews indicate that the overall rate of serious adverse events associated with mifepristone use is very low. However, patients should be prepared to experience a higher rate of expected short-term effects, such as pain and bleeding, compared to a placebo group.

Q: What does 'contraindication' mean in the context of Mifestad's use?

A contraindication is a critical regulatory term indicating that the medicine should never be used under certain conditions. This is because the risk to the patient, such as those with certain adrenal gland or hemorrhagic problems, is officially deemed too high to permit use.

Q: Are there studies examining Mifestad's use in pediatric populations?

Yes, official regulatory labeling confirms that safety and effectiveness are established in pregnant patients 17 years of age and younger, which represents an adolescent pediatric group. This information is based on data from relevant studies.

Q: Is Mifestad available as a generic medicine?

Official drug listings confirm that a lower-cost generic version of the active ingredient, mifepristone, is available. The generic version contains the same active drug and is regulated to meet the same standards as the brand-name medicine.

Storage and Handling

Official labeling requires Mifestad tablets to be stored at controlled room temperature, specifically 25 C (77 F), with permitted temperature excursions between 15 C and 30 C (59 F and 86 F). The medication must be kept in a closed container, away from excessive heat and protected from both freezing and direct light or moisture. This temperature control is mandatory to maintain the product's stability.

Child Safety and Disposal

The product must be kept out of the reach of children as a critical safety requirement. Disposal instructions advise patients to consult a healthcare professional or pharmacist for guidance on discarding any unused or expired medicine. In clinical settings, pharmaceutical waste must be handled according to established hazardous waste guidelines.